
    
      Primary objectives:

        -  describe cancer patients with COVID-19 and their clinical course;

        -  identify predictors of the most severe clinical course;

        -  identify prognostic factors; Secondary objectives

        -  Monitor patients with urological tumors with particular attention;

        -  Dosing parameters of inflammation such as IL-6 and IFNÎ±;

        -  Measure the ACE2 levels.

      Patients with oncological pathology who contracted COVID 19 infection from January 1, 2020
      until the WHO declaration of the end of the pandemic will be studied.
    
  